Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Patent Expiration
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic is Used for correcting hypophosphatemia in adults and pediatric patients 12 years of age and older. It was first introduced by Cmp Development Llc
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Patents
Given below is the list of patents protecting Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Potassium Phosphates In 0.9% Sodium Chloride | US11813291 | Ready-to-use potassium phosphates in sodium chloride solutions | Oct 12, 2041 | Fresenius Kabi Usa |
| Potassium Phosphates In 0.9% Sodium Chloride | US11925661 | Ready-to-use potassium phosphates in sodium chloride solutions | Oct 12, 2041 | Fresenius Kabi Usa |
| Potassium Phosphates | US10632150 | Potassium phosphates composition for injection | Apr 19, 2039 | Cmp Dev Llc |
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic's Family Patents
Explore Our Curated Drug Screens
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic Generic API Manufacturers
Several generic applications have been filed for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. The first generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic was by American Regent Inc and was approved on Oct 2, 2023. And the latest generic version is by Cipla Ltd and was approved on Jan 24, 2025.
Given below is the list of companies who have filed for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic generic, along with the locations of their manufacturing plants worldwide.
1. AM REGENT
American Regent Inc has filed for 3 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Am Regent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 2, 2023 |
| 11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 2, 2023 |
| 1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 2, 2023 |
2. AMNEAL
Amneal Eu Ltd has filed for 3 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 10, 2023 |
| 3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 10, 2023 |
| 11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 10, 2023 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
3. CIPLA
Cipla Ltd has filed for 3 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 11.8GM/50ML(236MG/ML); 11.2GM/50ML(224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jan 24, 2025 |
| 1.18GM/5ML(236MG/ML); 1.12GM/5ML(224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jan 24, 2025 |
| 3.54GM/15ML(236MG/ML); 3.36GM/15ML(224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jan 24, 2025 |
Manufacturing Plant Locations New
Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
4. SOMERSET THERAPS LLC
Somerset Therapeutics Llc has filed for 2 different strengths of generic version for Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic. All of these versions come by the name POTASSIUM PHOSPHATES. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 11, 2024 |
| 1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 11, 2024 |